New Randomized Controlled Trial Demonstrates the Efficacy of Daxor’s BVA Guided-Care in Heart Failure Patients Read more about New Randomized Controlled Trial Demonstrates the Efficacy of Daxor’s BVA Guided-Care in Heart Failure Patients
Daxor Corporation Awarded New Patent for Remote Monitoring of Blood Volume Read more about Daxor Corporation Awarded New Patent for Remote Monitoring of Blood Volume
Expert Panelists Advocate Use of Daxor’s Technology to Optimize Treatment at Heart Failure Society of America Annual Scientific Meeting Read more about Expert Panelists Advocate Use of Daxor’s Technology to Optimize Treatment at Heart Failure Society of America Annual Scientific Meeting
New Data from Banner University Medicine Demonstrating Effectiveness of BVA-100® Use in Ambulatory Heart Failure Patients Presented at Heart Failure Society of America Annual Scientific Meeting Read more about New Data from Banner University Medicine Demonstrating Effectiveness of BVA-100® Use in Ambulatory Heart Failure Patients Presented at Heart Failure Society of America Annual Scientific Meeting
JACC-HF Reports Successful Heart Failure Trial With Daxor BVA-100® Read more about JACC-HF Reports Successful Heart Failure Trial With Daxor BVA-100®
JACC-HF Study Compares Daxor’s BVA-100® Volume Metric to CardioMEMS® Pressure Metric in Heart Failure Patients Read more about JACC-HF Study Compares Daxor’s BVA-100® Volume Metric to CardioMEMS® Pressure Metric in Heart Failure Patients
Cytokinetics Announces Start of MAPLE-HCM, a Phase 3 Clinical Trial of Aficamten Compared to Metoprolol in Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy Read more about Cytokinetics Announces Start of MAPLE-HCM, a Phase 3 Clinical Trial of Aficamten Compared to Metoprolol in Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy
U.S. Food and Drug Administration Approves Addition of Positive Data from Phase 3 VALOR-HCM Study to CAMZYOS® (mavacamten) Label Read more about U.S. Food and Drug Administration Approves Addition of Positive Data from Phase 3 VALOR-HCM Study to CAMZYOS® (mavacamten) Label
Daxor Accelerates Blood Volume Analysis Adoption with the Launch of ezBVA Lab Services Read more about Daxor Accelerates Blood Volume Analysis Adoption with the Launch of ezBVA Lab Services
Andexxa Phase IV trial stopped early after achieving pre-specified criteria on haemostatic efficacy versus usual care Read more about Andexxa Phase IV trial stopped early after achieving pre-specified criteria on haemostatic efficacy versus usual care
